EGFR and familial primary hypomagnesemia: Targeted therapies like epidermal growth factor receptor (EGFR) inhibitors, used in metastatic CRC, can cause electrolyte disturbances, particularly hypomagnesemia, which can prolong QT interval and increase the risk of fatal arrhythmias and sudden cardiac death [10].